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Abstract
The new Dutch guidelines on hereditary and familial ovarian carcinoma recommend genetic testing of all patients with epithelial
ovarian cancer (EOC). With this study, we aimed to obtain insight into (1) the acceptance and timing of the offer of genetic
counseling in women with EOC, (2) reasons for accepting or declining genetic counseling, and (3) psychological differences
betweenwomenwho did and did not have genetic counseling. Amulticenter questionnaire survey was performed in patients with
EOC in four Dutch oncology centers. The questionnaire addressed whether, how, and when genetic counseling was offered,
women’s arguments to accept or decline genetic counseling, and included the Cancer Worry Scale (CWS) and the Hospital
Anxiety and Depression Scale (HADS). A total of 67 women completed the questionnaire, of which 43 had genetic counseling.
Despite a wide variability in the timing of the offer of genetic counseling, 89% of the women were satisfied with the timing. No
significant differences were found between the CWS and HADS scores for the timing of the offer of genetic counseling and
whether or not women had genetic counseling. Taking the small sample size into account, the results tentatively suggest that
genetic counseling may have limited impact on the psychosocial wellbeing of women with EOC. Therefore, we assume that
implementation of the new guidelines offering genetic counseling to all patients with EOC will not cause considerable additional
burden to these patients.
Keywords Ovarian carcinoma . Genetic counseling . Psychological wellbeing . Genetic testing
Introduction
Epithelial ovarian, peritoneal, and fallopian tube carcinoma
(EOC) is the seventh most common cancer affecting women
worldwide. In 2012, approximately 239,000 women
worldwide were diagnosed with EOC and 151,000 women
died of EOC that same year (Ferlay et al. 2012). In the
Netherlands, 1200 to 1300 women are diagnosed with EOC
every year (Dutch Cancer Registry 2015). EOC is often diag-
nosed at an advanced stage and is then associated with a poor
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prognosis. The 5-year survival of high-grade serous EOC is
20–60% (IKNL 2012). Around 10–20% of EOC is hereditary,
of which the BRCA1 and BRCA2 genes account for the ma-
jority (Alsop et al. 2012;Walsh et al. 2011; Zhang et al. 2011).
A minority of hereditary EOC is caused by germline muta-
tions in other genes, e.g., RAD51D, RAD51C, BRIP1, and the
mismatch repair genes (Lynch syndrome) (Loveday et al.
2011; Malander et al. 2006; Meindl et al. 2010; Rafnar et al.
2011). Identification of a germline mutation facilitates the
identification of healthy family members with a mutation in
EOC susceptibility genes. In these individuals, prevention of
EOC and related types of cancer can be lifesaving.
Furthermore, nowadays, identification of germline mutations
may have implications for the treatment of women with EOC,
since PARP inhibitors are most effective in women with re-
current EOC with a somatic or germline BRCA1 or BRCA2
mutation (Mirza et al. 2016). Although serum CA-125 mea-
surements and transvaginal ultrasound have long been the
recommended screening tools for women at increased risk
for EOC, those screening methods have been proven ineffec-
tive (Hermsen et al. 2007; van der Velde et al. 2009).
Nowadays, a bilateral risk-reducing salpingo-oophorectomy
is recommended for female BRCA mutation carriers
(Rebbeck et al. 2009). A majority of serous EOC appears to
originate from dysplastic lesions in the distal fallopian tube;
ongoing studies will demonstrate whether salpingectomy
leads to delayed choice for oophorectomy (Erickson et al.
2013). In patients with EOC, a substantial part of the germline
BRCA1/2 mutation carriers are missed when applying criteria
for genetic testing, such as age of onset, family history, and
histology (Arts-de Jong et al. 2016). Therefore, the recently
accepted Dutch guidelines on EOC recommend genetic
counseling and the offer of a DNA test for BRCA1 and
BRCA2 to all patients with EOC, irrespective of histology,
family history, or age at diagnosis. Depending on personal
and family history, complementary genetic tests (e.g. for
Lynch syndrome) can be considered (IKNL 2015). In line
with this, other international guidelines also advise to offer
genetic counseling to all patients with EOC, e.g., in the USA
(NCCNGuidelines version 1.2018: Breast and/or ovarian can-
cer genetic assessment). Concerns may rise about the burden
and timing of offering genetic counseling to this group of
women. In patients with EOC from different countries, accep-
tance rates of genetic counseling range from 60–99% (Alsop
et al. 2012; Dekker et al. 2013; Majdak et al. 2005; Malander
et al. 2006; Pal et al. 2005; Yazici et al. 2002). In the only
available Dutch study, 25 of 35 patients with EOC accepted
genetic testing. The lack of a correlation between the accep-
tance rate and time since diagnosis suggests that timing did
not influence the uptake of genetic counseling (Dekker et al.
2013).
So far, little is known about the psychosocial impact of
genetic counseling of women who have recently been
diagnosed with EOC. One study investigating the psychoso-
cial impact of genetic testing for BRCA mutations found no
increase in general anxiety, depression, or psychological dis-
tress during genetic counseling or 1 year afterwards in patients
with a personal or family history of breast cancer or EOC
(Bish et al. 2002). Others reported that offering genetic
counseling to breast cancer patients during treatment did not
lead to short-term or long-term adverse effects (Baars et al.
2014; Ringwald et al. 2016; Schlich-Bakker et al. 2008). To
our knowledge, only one study has focused on the timing of
genetic counseling in patients with EOC so far (Bjornslett
et al. 2015). This latter study used the Multidimensional
Impact of Cancer Risk Assessment (MICRA) in a large group
of patients with EOC that underwent genetic counseling. The
MICRAmeasures the specific impact of result disclosure after
genetic testing. The authors reported that cancer-related dis-
tress and a positive BRCA result had the strongest association
with the MICRA scores. However, the time from diagnosis/
disclosure to the survey was not related to the MICRA score.
The present questionnaire-base study assessed the burden
and timing of offering genetic counseling to women in the
Netherlands with EOC. The aim was to obtain insight into
whether women with EOC are inclined to accept or decline
genetic counseling, their reasons for doing so, their views on
the timing of the offer in the course of their disease, by which
professional genetic counseling should be offered and what




In this multicenter study, we used a questionnaire for eligible
patients with EOC, 6–12 months after their initial diagnosis.
Inclusion criteria were a recent diagnosis or recurrence of
EOC. Excluded were patients with a known genetic predispo-
sition for EOC and/or inadequate proficiency in Dutch
language.
Procedures
Between April 2014 and December 2015, consecutive pa-
tients with EOC from four Dutch oncology centers
(University Medical Center Groningen; Amsterdam UMC,
location AMC; the Netherlands Cancer Institute Amsterdam;
Radboudumc Nijmegen) were informed about the study by
their gynecologist and received an information sheet and in-
formed consent form. On the informed consent form, women
could indicate whether they consented to receive a question-
naire around 6 months after their initial diagnosis. They were
asked to return the consent form to the investigators by mail
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(an envelope was provided). Due to practical constraints, we
could not record how many information sheets and informed
consents were handed out. Consenting women received a pa-
per or digital questionnaire, depending on the woman’s pref-
erence. The local Medical Ethical Committee deemed that the
Medical Research Involving Human Subjects Act was not
applicable for this study. Therefore, a formal review by the
Medical Ethics Committee was not required.
Instrumentation
The questionnaire consisted of three parts (A, B, C). In part A,
demographic and medical information (moment of diagnosis,
treatment, personal history, and family history of cancer) were
collected. Part B consisted of questions about whether, how,
and when genetic counseling was offered and reasons to ac-
cept or decline genetic counseling. Genetic counseling was
defined as any consultation at the department of clinical ge-
netics, irrespective of whether a DNA test was performed.
Reasons to accept or decline genetic counseling were
inventoried by providing a checklist with response options
(see Table 3 for items) supplemented with an Bopen text^
box to allow for additional reasons. Patients were also asked
for their opinion regarding the offer of genetic counseling
(answered on a 5-point Likert scale). The questionnaire did
not address the outcomes of genetic counseling, and we had
no informed consent to collect these data. Part C consisted of
the Dutch versions of the Cancer Worry Scale (CWS) and the
Hospital Anxiety and Depression Scale (HADS). The CWS is
a validated scale to assess cancer-specific distress, consisting
of eight items answered on a 4-point Likert scale, resulting in
scores ranging from 8 to 32 (Douma et al. 2010; Lerman et al.
1994; Lerman et al. 1991). The higher the score, the higher the
level of distress. The HADS is a validated 14-item question-
naire investigating anxiety (HADS-A) and depression
(HADS-D) (Spinhoven et al. 1997; Zigmond and Snaith
1983). Both subscales of the HADS consist of seven items
answered on a 4-point Likert scale, resulting in scores from
0 to 21. Higher scores indicate a higher level of anxiety or
depression. In the present study, Cronbach’s alphas for the
CWS, HADS-A, and HADS-D were 0.92, 0.86, and 0.83,
respectively, implying good internal consistency.
Data analysis
For this study, only available data were analyzed and any
missing data, due to some questions not being answered, were
ignored. An independent samples t test was used to compare
the age of women who did and who did not return their ques-
tionnaire. Descriptive statistics were used to explore the de-
mographic andmedical characteristics of the participants. Chi-
squared tests were used to test for differences between women
who had genetic counseling and those who did not, regarding
age, education level, previous cancer, presence of a first-
degree family member with cancer, the moment in treatment
and timing of the offer of genetic counseling. To address psy-
chological wellbeing and possible adverse effects of genetic
counseling, independent t tests and one-way analyses of var-
iance in case of > 2 groups were used to compare differences
in the CWS scores between groups differing in the timing of
the offer of genetic counseling and whether or not women had
genetic counseling. Since the outcomes of the HADS-A and
HADS-D, both in the entire group and in some of the sub-
groups, were not normally distributed (assessed visually and
by the Shapiro-Wilk test), the Mann-Whitney U test and the
Kruskal-Wallis test were used to compare the HADS scores.
All data were analyzed using SPSS for Windows (version
19.0; SPSS; IBM Corp).
Results
A total of 91 women provided informed consent. Of these
women, 90 (99%) consented to receive a questionnaire and
67/90 (74%) returned their (partially) completed
questionnaire.
Part A: patient characteristics
General characteristics of the participating women are present-
ed in Table 1. Mean age of the participants was 64 years (SD
11.7), which was not significantly different from the women
who did not return their questionnaire (64 vs 67 years; p =
0.29). Amedical history of cancer, besides EOC, was reported
by 30% of the women (8 with breast cancer, 8 skin cancer, 1
pancreatic cancer, 1 cervical cancer, 1 stomach cancer, and 1
with kidney cancer).
Part B: experience with genetic counseling
Of the 67 participants, 43 received genetic counseling. There
were no significant differences in age, educational level, pre-
vious cancer, presence of a first-degree family member with
cancer, moment in treatment, moment of the offer of genetic
counseling, and how often women wonder about their cancer
being hereditary between women who received genetic
counseling and women who did not (yet) receive genetic
counseling (Table 1). Of the 20 women who did not have
genetic counseling yet, 12 reported they were planning to do
so within 6 months, 2 were planning to do so within a period
longer than 6 months, 4 were not planning to undergo genetic
counseling, and 2 had not yet decided.
Regarding the offer of genetic counseling, for 29 women,
this was offered by the gynecologist, for 12 by the clinical
geneticist, and 8 women reported that both the gynecologist
and clinical geneticist offered genetic counseling. Very few
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women were informed by their general practitioner (n = 2),
radiotherapist (n = 1), surgeon (n = 5), nurse (n = 2), and/or
family members (n = 6). Ten women reported that genetic
counseling was not offered to them. Of those who received
an offer, 98% appreciated the offer and felt that they had been
informed by the appropriate person. Nevertheless, women felt
very different about the offer of genetic counseling (Fig. 1).
For example, 24 women felt the information they received
about genetic counseling was not useful. Furthermore, 22
women would rather have not received the information about
genetic counseling. All except two women were satisfied with
the timing of the offer of genetic counseling. The two dissat-
isfied women preferred to postpone the referral until after
treatment and one of these women preferred to wait until a
few months later (Table 2). Participants were also asked about
their considerations regarding whether to accept or decline
genetic counseling, irrespective of their own final decision
(Table 3).
Part C: psychological distress
The mean score on the CWS was 17.0 (SD 5.5). The median
score on the HADS-A was 6.0 (range 0–13) and on the
HADS-D was 4.0 (range 0–15). Table 4 presents comparisons
between the CWR and HADS scores for the timing of the
offer of genetic counseling and whether or not women had
genetic counseling. There were no significant differences in
these items. Also, there were no significant differences in the
CWS, HADS-A, and HADS-D scores depending on age, level
of education, presence of a first-degree relative with cancer or
Fig. 1 Patients’ reaction to the
offer of genetic counseling
Table 1 Comparison of EOC patients who did and did not have genetic counselinga
Total Genetic counseling No genetic counseling P value
Age > 60 47 29 16 0.30
≤ 60 20 14 4
Education Primary/middle 43 28 12 0.79
High/university 22 14 7
Previous cancer No 46 27 15 0.21
Yes 20 16 4
First degree relative with cancer No 22 16 5 0.34
Yes 45 27 15
Treatment finished No 16 13 2 0.08
Yes 51 30 18
Genetic counseling discussed Before start of treatment 21 17 4 0.47
During treatment 22 14 7
After treatment 14 9 5
Wonder about cancer being hereditary Never 13 7 6 0.32
Yes, sometimes 30 21 9
Yes, often 19 15 4
a Subgroups do not all count up to 67 as the result of missing data
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the moment in treatment (data not shown). Interestingly, wom-
en who reported to have a history of another type of cancer
had significantly lower scores for cancer worry, anxiety, and
depression: p values were < 0.001, 0.001, and 0.011 for the
CWS, HADS-A, and HADS-D, respectively.
Discussion
In this study, the participants generally appreciated the offer of
genetic counseling and were content with the timing of the
offer, and the uptake of genetic counseling 6–12 months after
the diagnosis was high. No association was found between
psychological distress and the moment of discussing genetic
counseling. Furthermore, no difference was found in psycho-
logical distress between women who received genetic
counseling and those who had not (yet) received genetic
counseling. Therefore, there seem to be no psychological ob-
jections to comply with the new Dutch guidelines.
Most women reported that genetic counseling was offered
by their gynecologist. This is as expected since, in the
Netherlands, the gynecologist makes the diagnosis and
coordinates treatment. However, 12 women reported that they
received the offer for genetic counseling from their clinical
geneticist. This is unexpected, since women have access to
clinical genetic care only after referral by another clinician.
It is unlikely that referral takes place without mentioning this
to the patient. However, it is possible that the women had
forgotten that they had received information about genetic
counseling from the gynecologist or another referring clini-
cian. This issue has been reported earlier (Vogel et al. 2018).
Also, the referring clinician may not have spent sufficient time
on the subject or the women may have forgotten the informa-
tion due to the high impact of the diagnosis and/or treatment of
EOC. Therefore, some women may have (erroneously) expe-
rienced being informed by the clinical geneticist only.
A relatively large proportion of women reported that the
offer for genetic counseling was not useful to them and that
they would rather have not received this information. This
might be a worrisome finding and seems conflicting with the
fact that 98% appreciated the offer for genetic counseling.
Although we did not ask why women felt this way, they
may have experienced insufficient quality of the information
supply, and/or the content of the information they received. It
Table 3 Reasons to accept or decline genetic counselingb
Arguments to accept genetic counseling n (%) Arguments to decline genetic counseling n (%)
To discover cancer early in myself or family members
For my children
For my family
It is important for future treatment
To know the cause of my ovarian cancer
To have role in cancer prevention myself
Because my family will appreciate it
More information gives me the feeling of having control
To be certain











Small chance of a hereditary cause
It is not important for treatment
There are many other things to care about
Afraid for results
I do not feel to think about my cancer risk
I think my family gets worried
It will make me anxious
Insurance consequences for me and family
I have no children
I do not want to go to hospital more often
It is too time consuming













n number of participants reporting this argument
b All reasons listed were choices presented in the questionnaire. Participants could select any that they felt applied. No participants added additional
reasons in the open text box
Table 2 Women’s opinion about
the timing of the offer for genetic
counseling
Moment genetic counseling was offered Good timing Suboptimal timing Do not know Total
At diagnosis 3 0 1 4
Before start of treatment 17 0 0 17
During CT, before surgery 6 0 1 7
During CT, after surgery 12 1 1 14
After completion of treatment 13 1 0 14
Do not remember 0 0 1 1
Total 51 2 4 57
CT chemotherapy
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may also have to dowith the fact that genetic counseling could
not take place at the moment of receiving the information.
Further research is required to further understand these
reactions.
At the moment of completing the questionnaire, 68% of the
participants had received genetic counseling and most of the
remaining women were considering genetic counseling in the
near future. Only four women were not considering genetic
counseling. This high uptake of genetic counseling is in line
with other literature (Alsop et al. 2012; Dekker et al. 2013;
Majdak et al. 2005; Malander et al. 2006; Pal et al. 2005;
Yazici et al. 2002). That most women were planning to have
genetic counseling in the near future might be reflected in the
lack of a difference in the variables presented in Table 1.
Previous studies reported that (as in our study), in patients
with EOC and colorectal carcinoma, the most common rea-
sons to accept genetic counseling are that patients want to
obtain information on their own cancer risk and that of family
members and to receive appropriate surveillance advice
(Dekker et al. 2013; Esplen et al. 2007). In women with
EOC, reasons to decline genetic counseling were the absence
of relatives for whom genetic counseling would be relevant,
being too ill to come to the hospital or being not willing to
come to the hospital (Dekker et al. 2013; Pal et al. 2005).
Emotional concerns, such as being afraid of the test result
and worrying family members, did not emerge as relevant in
these latter studies but were mentioned in focus groups by
patients with breast cancer and EOC (Kne et al. 2017; Vogel
et al. 2018). In the present study, the women also mentioned
emotional reasons. It is important that clinicians are aware of
these considerations and discuss them either before or after
referral to a genetics department.
In the present study, for the four women not considering
genetic counseling, their reasons for declining genetic counsel-
ing were making their family worried (n = 2), having other
things to care about (n = 2), family does not want it (n = 1),
having no children (n = 1), small chance of hereditary cause
(n = 1), and not wanting to go to the hospital again (n = 1).
Interestingly, they did not mention being afraid of the result
or being anxious themselves, and they scored relatively low on
cancer worry, anxiety, and depression (CWS mean 13.8;
HADS-A median 2; HADS-D; median 2.5). These women
might be less worried in general or less worried about their
cancer being hereditary. Therefore, they might be less inclined
to opt for genetic counseling. However, more research is need-
ed to substantiate this assumption. Ideally, all patients declin-
ing genetic counseling should be empowered to make an in-
formed decision. For example, patients who have no children
might have other family members at risk for (ovarian) cancer
or the patients mentioning a small chance of a hereditary cause
might underestimate their risk. Indeed, it has been shown that
cancer patients may have a lack of knowledge regarding ge-
netics (Dekker et al. 2013; Geer et al. 2001; Vogel et al. 2018).
Therefore, it is important that the referring physician thorough-
ly explores a woman’s reasons for declining genetic counsel-
ing. Interventions, such as patient information sheets and/or
digital tools to support decision-making, might help tackle this
issue (Grimmett et al. 2018).
Guidelines on genetic counseling for patients with EOC do
not indicate the best moment to offer and plan genetic counsel-
ing (IKNL 2015; NCCN Guidelines version 1.2018: Breast
and/or ovarian cancer genetic assessment). In the present
study, most patients received the offer for genetic counseling
shortly after the diagnosis of EOC and before the start of
treatment. However, there was considerable variability in the
timing. In a previous study on Dutch patients with breast can-
cer, no adverse psychological effects were reported after ge-
netic counseling and testing that occurred shortly after diag-
nosis and before treatment (Wevers et al. 2011). Similarly, we
found no significant difference in distress and anxiety scores
for the different moments of discussing genetic counseling.
When evaluating the timing of the offer of genetic counseling,
almost all women were satisfied with when it occurred.
Altogether, this suggests that there is no Bbest^ moment to
discuss genetic counseling or that caretakers tailor the timing
of information provision to the needs of their individual pa-
tients. Moreover, after having received the offer, women
choose the timing of the actual genetic counseling themselves.
Table 4 Cancer worry, anxiety, and depression according to timing of the offer for genetic counseling and whether or not women had genetic
counseling
CWS HADS-anxiety HADS-depression






20 17.8 5.2 0.32 20 6.5 0–13 0.24 21 5.0 0–12 0.77
During treatment 22 18.2 5.7 20 6.0 0–12 21 5.0 0–10
After treatment 14 15.4 5.7 14 3.5 0–11 14 4.0 0–15
Had genetic
counseling
No 20 17.8 5.6 0.48 18 7.0 0–12 0.22 19 4.0 0–12 0.66
Yes 41 16.7 5.6 42 5.0 0–13 43 3.0 0–15
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Of note, in the present study, the overall median anxiety
and depression scores in this study (6.0 and 4.0 respectively)
are higher than reported for the general population and in
cancer patients. For example, in a random sample of Dutch
individuals aged 57–65 years, the mean HADS-A score was
3.9 and the mean HADS-D score was 3.7 (Spinhoven et al.
1997). A study among women with breast cancer or a gyne-
cologic cancer reported a mean HADS-A score of 3.9
24 weeks after surgery (Stafford et al. 2013). In women with
cervical carcinoma, the mean HADS-A score was 5.6 and 5.4
(early stage and locally advanced respectively) and the
HADS-D score was 2.7 and 3.1 6 months after surgery
(Ferrandina et al. 2012). In the present study, the mean CWS
score (17.0) is also higher than previously reported in other
types of cancer. In a study on breast cancer patients, the CWS
score was 13.7 and 14.5 (rapid genetic testing and usual care
respectively) 6 months after diagnosis. Although no CWS or
HADS scores specific for EOC are available, they might be
higher than in other types of cancer because of the generally
worse prognosis of EOC. Higher scores might also reflect a
response bias, with more distressed women being more in-
clined to participate in a study aimed at assessing their expe-
riences. Strikingly, in our study, all distress scores were sig-
nificantly lower in the group of women who reported a history
of another type of cancer. To our knowledge, no previous
studies have reported a similar finding. A possible explanation
might be that women with a previous malignancy had ac-
quired coping strategies which they effectively apply when a
second malignancy is diagnosed.
With the extension of the indication for genetic testing in
patients with EOC and the rapidly changing treatment of
EOC, the timing and implementation of genetic counseling
in these patients may change. Knowing the germline BRCA
status before start of treatment may become increasingly im-
portant (George et al. 2016). In this light, our results suggest
that genetic testing can be safely discussed shortly after diag-
nosis. Furthermore, options such as genetic testing by the
gynecologist can also be explored.
The present study has several limitations. Based on the
experience of the gynecologists, we assume that a relatively
large number of patients did not return the informed consent
form. However, because we were unable to record how many
information sheets and informed consents were handed out
and to which patients, we do not know whether there is a
difference between participating and non-participating wom-
en. We estimate that about 500 women were treated for EOC
in the participating hospitals during the study period, resulting
in an estimated inclusion rate of 18% (90/500) of all eligible
women. Some selection bias may have occurred since women
with a positive feeling about genetic testing or those with a
relatively good prognosis might have been more inclined to
participate. On the other hand, the relatively high scores on the
CWS and HADS might indicate a bias of more distressed
women being inclined to participate. A bias might have led
to an over- or underestimation of the uptake of genetic
counseling and the effect of genetic counseling on cancer
worry, anxiety, and depression. On the other hand, the bias
might be small since the uptake of genetic counseling was
comparable with earlier studies and there are no indications
for a trend towards an effect of genetic counseling on cancer
worry, anxiety, and depression. If less worried women are less
inclined to opt for genetic counseling, as mentioned above, a
bias towards more women interested in genetic counseling
might be a contributing factor in the generally high scores
on the CWS and HADS. Unfortunately, we did not record
the outcomes of genetic testing, including whether women
chose for a DNA test and the result of the test. These results
could have influenced our findings. Other factors to consider
when interpreting the results are the relatively small sample
size and the fact that some of the questions addressed events in
the past, possibly leading to a recall bias.
In conclusion, offering genetic counseling after the diagno-
sis of EOC appears to have limited impact on the psychosocial
wellbeing of these patients. Therefore, we assume that imple-
mentation of the new Dutch guideline on hereditary EOC
causes no unjustified additional burden to women with
EOC. However, more systematic prospective studies are need-
ed to confirm our results. Investigation of other hypotheses
from this study may include the generally high scores on the
CWS and HADS in patients with EOC and the lower scores in
patients who declined genetic counseling.
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